Abstract
Prostatic acid phosphatase (PAP) is a 100 kDa glycoprotein synthesized by well-differentiated prostatic gland columnar epithelia and secreted in large quantity in seminal fluid (Hassan et al., Expert Rev Anticancer Ther 10:1055–1068, 2010). PAP is present in elevated concentrations in the serum of men who have prostate cancer or other prostatic diseases (Hassan et al., Expert Rev Anticancer Ther 10:1055–1068, 2010). The PAP gene is located along the long arm of chromosome 3 at locus 21 (3q21), and the protein product exists as intracellular, transmembrane, and secreted forms, with slightly different biochemical properties differentiating each of these (Hassan et al., Expert Rev Anticancer Ther 10:1055–1068, 2010; Solin et al., Biochem Biophys Acta 1048:72–77, 1990).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Becker JT, Olson BM, Johnson LE, et al. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother. 2010;33(6):639–47.
Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000;6:2175–82.
Dattoli M, Wallner K, True L, et al. Long-term prostate cancer control using Palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension. Urology. 2007;69:334–7.
Fong L, Ruegg CL, Brockstedt D, et al. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization; implications for immunotherapy of prostate cancer. J Immunol. 1997;159:3113–7.
Han M, Piantadosi S, Zahurak ML, et al. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology. 2001;57:707–11.
Hassan M, Aijaz A, Ahmad F. Structural and functional analysis of human prostatic acid phosphatase. Expert Rev Anticancer Ther. 2010;10(7):1055–68.
Johnson DE, Prout GR, Scott WW, et al. Clinical significance of serum acid phosphatase levels in advanced prostatic carcinoma. Urology. 1976;8:123–6.
Johnson LE, Frye TP, Arnot AR, et al. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine. 2006;24:293–303.
Johnson LE, Frye TP, Chinnasamy N, et al. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol Immunother. 2007;56:885–95.
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucell-T immunotherapy for castration-resistant prostate cancer. NEJM. 2010;363(5):411–22.
Lin MF, Lee MS, Zhou XW, et al. Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells. J Urol. 2001;166:1943–50.
McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. JCO. 2009;27(25):4047–54.
Meng TC, Lee MS, Lin MF. Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene. 2000;19(22):2664–77.
Moul JW, Connelly RR, Perahia B, et al. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. J Urol. 1998;159:935–40.
Quintero IB, Araujo CL, Pulkka AE, et al. Prostatic acid phosphatase is not a prostate specific target. Cancer Res. 2007;67(14):6549–54.
Reif AE, Schlesinger RM, Fish CA, et al. Acid phosphatase isozymes in cancer of the prostate. Cancer. 1973;31:689–99.
Romas NA. Prostatic acid phosphatase: current concepts. Semin Urol. 1983;1:177–85.
Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. JCO. 2000;18(23):3894–903.
Solin T, Kontturi M, Pohlmann R, et al. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analysis. Biochem Biophys Acta. 1990;1048(1):72–7.
Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909–16.
Taira A, Merrick G, Wallner K, et al. Reviving the acid phosphatase test for prostate cancer. Oncology. 2007;21(8):1003–10.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this entry
Cite this entry
Adelberg, D.E., Dahut, W. (2017). PAP. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0717-2_28
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0717-2_28
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0716-5
Online ISBN: 978-1-4419-0717-2
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences